eMed vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.
About
eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.